UBS upgraded Revvity (RVTY) to Buy from Neutral with a price target of $115, down from $145. The firm believes Revvity’s growth algorithm could be upside differentiated vs. peers and concerns on China diagnostics are overblown, the analyst tells investors in a research note. Self help and differential exposure shield life sciences from the worst of industry challenges, UBS argues, adding that takeaways from recent doctor diligence on autoimmune diagnostics suggest both strong growth prospects and a greater competitive moat than the firm had appreciated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity Reports Strong Q1 2025 Financial Results
- Revvity’s Resilience and Strategic Positioning Earns Buy Rating Amidst Macroeconomic Challenges
- Revvity price target lowered to $125 from $127 at Baird
- Revvity’s Mixed Performance and Cautious Outlook Justify Hold Rating
- Revvity’s Strong Performance and Strategic Management Justify Buy Rating